Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Gothenburg – page 2

385 clinical trials in Gothenburg, Sweden across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Gothenburg at a glance
385
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

385 trials in Gothenburg

Open in trial search

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Sponsor:AnaCardio AB

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Janssen Cilag International

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

A study of hydroxyurea added to standard drug combination to assess safety and effectiveness in adults with relapsed or refractory acute myeloid leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Karolinska University Hospital

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Revolution Medicines Inc.

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Gothenburg

What the registry says about research in the country

01 Oncology and Hematologic Malignancies

In Goteborg, a large share of trials focus on cancer and blood disorders, ranging from solid tumors to leukemia and lymphoma. These studies are designed to test new treatment options, improve survival, and refine care for patients with both early and advanced disease.

  • Breast cancer, lung cancer, and prostate cancer
  • Leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes
  • Melanoma, pancreatic cancer, and other advanced solid tumors
  • Testing new combinations, targeted treatments, and post-surgery approaches

Several studies also explore better ways to match therapy to tumor biology, aiming to make treatment more effective and better tolerated.

02 Cardiovascular Research

Heart and vascular disease is another major research area in this city, with trials covering common and high-risk conditions such as coronary disease, heart failure, stroke, and aneurysm. The overall goal is to improve prevention, emergency care, and long-term outcomes.

  • Heart failure, including preserved and reduced ejection fraction forms
  • Coronary artery disease, myocardial infarction, and atrial fibrillation
  • Stroke prevention and treatment after acute events
  • Aortic aneurysm, hypertension, and broader cardiovascular risk

These studies often evaluate whether new therapies can reduce complications, improve blood flow, or help patients avoid repeat events.

03 Respiratory and Pulmonary Diseases

Research in respiratory medicine is well represented, with studies addressing chronic lung disease, inflammatory airway conditions, and pulmonary vascular disorders. Many trials are aimed at easing symptoms and slowing functional decline.

  • Chronic obstructive pulmonary disease and asthma
  • Pulmonary arterial hypertension and related forms of pulmonary hypertension
  • Idiopathic pulmonary fibrosis and alpha-1 antitrypsin deficiency
  • Evaluating symptom control, lung function, and disease progression

Several trials also examine treatments for patients with overlapping heart and lung conditions, reflecting the complexity of real-world care.

04 Autoimmune and Inflammatory Conditions

Goteborg hosts a strong portfolio in immune-mediated diseases, including trials in rheumatology, gastroenterology, and systemic inflammatory disorders. The research focus is on reducing inflammation, preserving organ function, and improving daily quality of life.

  • Rheumatoid arthritis, Sjogren's syndrome, and systemic sclerosis
  • Crohn’s disease and ulcerative colitis
  • ANCA-associated vasculitis and chronic graft-versus-host disease
  • Testing therapies that calm abnormal immune activity and protect affected organs

These studies often look at whether newer treatments can provide better control than standard care while limiting long-term damage.

05 Neurology and Neurodegenerative Disorders

Nervous system diseases are an important part of the trial landscape, with studies spanning epilepsy, multiple sclerosis, Parkinson’s disease, stroke recovery, and dementia. The common aim is to improve function, slow decline, or prevent worsening symptoms.

  • Multiple sclerosis and progressive neurologic disease
  • Alzheimer’s disease and mild cognitive impairment
  • Epilepsy, Parkinson’s disease, and myasthenia gravis
  • Evaluating symptom relief, functional improvement, and disease-modifying potential

Some studies also explore treatments after stroke or brain injury, where preserving neurological function is a key priority.

06 Metabolic, Endocrine, and Kidney Disorders

Many trials in Goteborg address metabolic disease, endocrine disorders, and kidney conditions. This includes research on diabetes, obesity, lipid disorders, adrenal disease, and chronic kidney disease.

  • Type 1 diabetes, type 2 diabetes, and obesity
  • Chronic kidney disease, kidney transplant rejection, and IgA nephropathy
  • Hyperlipidemia, hypertriglyceridemia, and hyperkalemia
  • Testing new options for disease control, organ protection, and risk reduction

There is also work on rare hormone-related conditions and weight-management approaches for people with or without diabetes.

07 Dermatology, Allergy, and Immune-Mediated Skin Disease

Skin and connective tissue diseases form a notable research area, especially for chronic inflammatory conditions that can affect comfort, sleep, and self-esteem. Trials are exploring better control of symptoms and fewer relapses.

  • Atopic dermatitis and atopic hand eczema
  • Hidradenitis suppurativa and psoriasis-related inflammatory disease
  • Severe eczema and other persistent allergic skin conditions
  • Assessing new therapies to reduce inflammation and improve skin health

These studies are particularly relevant for patients whose symptoms remain difficult to control with standard treatment.

08 Gastroenterology, Liver, and Pancreatic Diseases

Clinical trials also cover a broad range of digestive system diseases, from inflammatory bowel disease to cancers of the liver, pancreas, and biliary tract. The aim is to improve both disease control and treatment outcomes.

  • Crohn’s disease, ulcerative colitis, and short bowel syndrome
  • Pancreatic cancer, colorectal cancer, and gastric cancer
  • Hepatocellular carcinoma, cholangiocarcinoma, and biliary tract cancer
  • Evaluating new therapies after surgery, for advanced disease, or to prevent relapse

Some studies focus on improving survival, while others look at postoperative recovery and longer-term disease control.

09 Psychiatry and Behavioral Health

Several trials in Goteborg address mental disorders and related behavioral health needs. The research is aimed at improving symptom management, daily functioning, and treatment options for patients with long-standing conditions.

  • Major depressive disorder and generalized anxiety disorder
  • Attention-deficit/hyperactivity disorder
  • Schizophrenia spectrum disorder
  • Testing new medicines and safer long-term approaches for psychiatric care

These studies may also explore whether treatment can improve attention, mood, and overall quality of life.

10 Hematology, Coagulation, and Vascular Inflammation

Research in blood disorders includes both inherited and acquired conditions, as well as complications linked to clotting and bleeding. The main goal is to refine supportive care and improve disease control.

  • Hemophilia and von Willebrand disease
  • Anemia, myelodysplastic syndromes, and essential thrombocythemia
  • Vasculitis and other inflammatory vascular disorders
  • Evaluating better ways to reduce bleeding, support blood production, and limit complications

Some studies also follow long-term safety in patients who have already received advanced blood cancer therapies.

11 Rare Diseases and Transplant-Related Research

This city also supports trials in rare diseases and transplant medicine, where patient numbers are smaller but the medical need is high. Research often focuses on protecting transplanted organs and addressing uncommon inherited conditions.

  • Transplant rejection after kidney, lung, or stem cell transplantation
  • Congenital adrenal hyperplasia and familial hypercholesterolemia
  • Transthyretin amyloid cardiomyopathy and other rare cardiac disorders
  • Studying long-term safety, organ protection, and improved disease management

Several of these trials are designed to make life easier for patients living with complex, chronic, or uncommon conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.